Clinical advantage and outcomes of computed tomography-based transvaginal hybrid brachytherapy performed only by sedation without general or saddle block anesthesia.
brachytherapy
cervical cancer
hybrid brachytherapy
interstitial brachytherapy
intracavitary brachytherapy
radiotherapy
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
30
12
2021
received:
29
07
2021
accepted:
21
01
2022
pubmed:
2
3
2022
medline:
23
11
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
Three-dimensional image-guided brachytherapy is the standard of care in cervical cancer radiotherapy. In addition, the usefulness of the so-called "hybrid brachytherapy (HBT)" has been reported, which involves the addition of needle applicators to conventional intracavitary brachytherapy for interstitial irradiation. To evaluate the clinical outcomes of CT-based HBT consisting of transvaginal insertion of needle applicators (CT-based transvaginal HBT) and only intravenous sedation without general or saddle block anesthesia. This is a retrospective chart review of patients who received definitive radiotherapy, including CT-based transvaginal HBT, between February 2012 and July 2019. The inclusion criteria were as follows: (i) histologically diagnosed disease, (ii) untreated cervical cancer, (iii) International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IVA disease in the 2008 FIGO staging system, and (iv) patients who underwent CT-based transvaginal HBT at least once in a series of intracavitary brachytherapy. Overall, 54 patients fulfilled the eligibility criteria in the present study. The median follow-up period was 32 (IQR, 19-44) months. No patient complained of symptoms such as persistent bleeding or abdominal pain after the treatment. The 3-year local control (LC), disease-free survival, and overall survival rates for all 54 patients were 86.6%, 60.3%, and 90.7% (95% CI [81.3%-100.0%]), respectively. The 3-year LC rate was 87.7% in patients with FIGO III-IVA and 90.4% in tumor size >6.0 cm. The incidence rate of late adverse events, grade ≥3, in the rectum and bladder was 0% and 1.8%, respectively. In the dose-volume histogram analyses, transvaginal HBT increased the dose of HR-CTV Considering the favorable clinical outcomes, CT-based transvaginal HBT may be a good option for treating cervical cancer.
Sections du résumé
BACKGROUND
Three-dimensional image-guided brachytherapy is the standard of care in cervical cancer radiotherapy. In addition, the usefulness of the so-called "hybrid brachytherapy (HBT)" has been reported, which involves the addition of needle applicators to conventional intracavitary brachytherapy for interstitial irradiation.
AIM
To evaluate the clinical outcomes of CT-based HBT consisting of transvaginal insertion of needle applicators (CT-based transvaginal HBT) and only intravenous sedation without general or saddle block anesthesia.
METHODS AND RESULTS
This is a retrospective chart review of patients who received definitive radiotherapy, including CT-based transvaginal HBT, between February 2012 and July 2019. The inclusion criteria were as follows: (i) histologically diagnosed disease, (ii) untreated cervical cancer, (iii) International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IVA disease in the 2008 FIGO staging system, and (iv) patients who underwent CT-based transvaginal HBT at least once in a series of intracavitary brachytherapy. Overall, 54 patients fulfilled the eligibility criteria in the present study. The median follow-up period was 32 (IQR, 19-44) months. No patient complained of symptoms such as persistent bleeding or abdominal pain after the treatment. The 3-year local control (LC), disease-free survival, and overall survival rates for all 54 patients were 86.6%, 60.3%, and 90.7% (95% CI [81.3%-100.0%]), respectively. The 3-year LC rate was 87.7% in patients with FIGO III-IVA and 90.4% in tumor size >6.0 cm. The incidence rate of late adverse events, grade ≥3, in the rectum and bladder was 0% and 1.8%, respectively. In the dose-volume histogram analyses, transvaginal HBT increased the dose of HR-CTV
CONCLUSION
Considering the favorable clinical outcomes, CT-based transvaginal HBT may be a good option for treating cervical cancer.
Identifiants
pubmed: 35229494
doi: 10.1002/cnr2.1607
pmc: PMC9675380
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1607Informations de copyright
© 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):598-604
pubmed: 26867888
Lancet. 2001 Sep 8;358(9284):781-6
pubmed: 11564482
Radiother Oncol. 2006 Jan;78(1):67-77
pubmed: 16403584
Brachytherapy. 2018 Sep - Oct;17(5):775-781
pubmed: 29941345
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
J Radiat Res. 2019 Jul 1;60(4):490-500
pubmed: 31111896
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1052-1062
pubmed: 32007365
BMC Cancer. 2014 Jun 17;14:447
pubmed: 24938757
BMC Cancer. 2019 Mar 12;19(1):221
pubmed: 30866877
J Contemp Brachytherapy. 2015 Jun;7(3):259-63
pubmed: 26207117
Radiother Oncol. 2015 Apr;115(1):78-83
pubmed: 25805517
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):491-8
pubmed: 17331668
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225
pubmed: 16034873
Cancer Rep (Hoboken). 2022 Nov;5(11):e1607
pubmed: 35229494
Lancet Oncol. 2021 Apr;22(4):538-547
pubmed: 33794207
J Radiat Res. 2017 Jul 1;58(4):543-551
pubmed: 27986859
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Brachytherapy. 2016 Sep-Oct;15(5):562-9
pubmed: 27474180
J Radiat Res. 2018 Jul 1;59(4):469-476
pubmed: 29986113
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Oncol Lett. 2020 Sep;20(3):2058-2074
pubmed: 32782524
Radiat Oncol. 2014 Oct 16;9:222
pubmed: 25319341
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):429-36
pubmed: 20542643
Jpn J Clin Oncol. 2010 Aug;40(8):795-9
pubmed: 20444747
Brachytherapy. 2019 Nov - Dec;18(6):771-779
pubmed: 31506225
Acta Oncol. 2013 Oct;52(7):1345-52
pubmed: 23905674
J Radiat Res. 2017 May 1;58(3):341-350
pubmed: 27837120
Radiother Oncol. 2021 Jul;160:273-284
pubmed: 34019918
Int J Clin Oncol. 2011 Aug;16(4):379-86
pubmed: 21331768
Radiother Oncol. 2009 Nov;93(2):311-5
pubmed: 19679365
Brachytherapy. 2017 Jan - Feb;16(1):161-166
pubmed: 27914911
N Engl J Med. 1999 Apr 15;340(15):1198-200
pubmed: 10202172
J Radiat Res. 2021 May 12;62(3):502-510
pubmed: 33532828
J Radiat Res. 2011;52(1):54-8
pubmed: 21293072
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):140-6
pubmed: 18922646
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):201-11
pubmed: 10924990